Detalhe da pesquisa
1.
A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer.
Gynecol Oncol
; 171: 106-113, 2023 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-36868112
2.
Comparative analysis of predictive values of the kinetics of 11 circulating miRNAs and of CA125 in ovarian cancer during first line treatment (a GINECO study).
Gynecol Oncol
; 159(1): 256-263, 2020 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-32712155
3.
Corrigendum to "A RAD51 functional assay as a candidate test for homologous recombination deficiency in ovarian cancer".
Gynecol Oncol
; 175: 194, 2023 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-37271667
4.
Safety and Efficacy of the mTOR Inhibitor, Vistusertib, Combined With Anastrozole in Patients With Hormone Receptor-Positive Recurrent or Metastatic Endometrial Cancer: The VICTORIA Multicenter, Open-label, Phase 1/2 Randomized Clinical Trial.
JAMA Oncol
; 8(7): 1001-1009, 2022 07 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-35551299
5.
Effect of Weekly Paclitaxel With or Without Bevacizumab on Progression-Free Rate Among Patients With Relapsed Ovarian Sex Cord-Stromal Tumors: The ALIENOR/ENGOT-ov7 Randomized Clinical Trial.
JAMA Oncol
; 6(12): 1923-1930, 2020 Dec 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33030515
6.
CA-125 ELIMination Rate Constant K (KELIM) Is a Marker of Chemosensitivity in Patients with Ovarian Cancer: Results from the Phase II CHIVA Trial.
Clin Cancer Res
; 26(17): 4625-4632, 2020 09 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-32209570